Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATRA with free AI briefings, catalyst countdowns, and dilution alerts.

ATRA · Atara Biotherapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.9M Cash on Hand
14.1mo Cash Runway
Follow ATRA by email Get an email when ATRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATRA, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-03-31 — BLA 37%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tabelecleucel Primary Progressive Multiple Sclerosis Phase 1/2 · NCT03283826 Terminated
CMV-pp65 CTLs Cytomegalovirus Phase 2 · NCT01646645 Completed
EBV-Specific Cytotoxic T-Lymphocyte EBV-induced Lymphomas Phase 1/2 · NCT00002663 Completed
Allogeneic Anti-CD19 CAR T-cells ATA3219 Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Phase 1 · NCT06256484 Terminated
Chimeric Antigen Receptor T-cells Malignant Pleural Mesothelioma (MPM) Phase 1 · NCT04577326 Active not recruiting
WT1-sensitized T cells Leukemia Phase 1 · NCT00620633 Completed
Cytomegalovirus-specific Cytotoxic T… CMV Viremia N/A · NCT03010332 No longer available

Also used in these trials (approved or third-party drugs, not ATRA's own candidates): Pembrolizumab, Cyclophosphamide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATRA holds $9.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations, an estimated runway of 14.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATRA files for a raise →

👥 Who Owns ATRA

Insiders 58.8% Other 5%+ holders 6.7% Institutions (46 holders) 34.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Panacea Innovation Ltd
10% owner
Insider 1,318,894 12.95% 2026-05-07
Gregory Austin Ciongoli
Director, 10% owner
Insider 1,221,395 11.99% 2026-06-09
Adiumentum Capital Fund I LP
Director, 10% owner · +377,193 options
Insider 1,209,395 11.87% 2025-05-16
EcoR1 Capital, LLC
10% owner
Insider 1,044,593 10.25% 2026-05-07
Adage Capital Management, L.P. Institution (13G, 5%+) 700,000 6.87% 2026-03-31
Point72 Asset Management, L.P. 5%+ holder (13G) 687,718 6.75% 2026-06-30
Redmile Group, LLC
Director · +3.22M options
Insider 636,852 6.25% 2026-07-22
Brian N Cherry
Director
Insider 166,486 1.63% 2026-09-04
AnhCo Nguyen
President and CEO, Director
Insider 132,775 1.30% 2026-08-17
Pascal Touchon
Director
Insider 77,955 0.77% 2025-06-10
Yanina Grant-Huerta
Chief Accounting Officer
Insider 49,636 0.49% 2026-05-18
William K Heiden
Director
Insider 34,188 0.34% 2026-06-09

Share count 10,188,438 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-01-10 EBVALLO BLA -12.9% -57% -66.8%

Browse all historical PDUFA outcomes →

Get the full ATRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.